141 related articles for article (PubMed ID: 7822205)
21. Topical treatment of New and Old World cutaneous leishmaniasis in experimental animals.
el-On J; Hamburger AD
Trans R Soc Trop Med Hyg; 1987; 81(5):734-7. PubMed ID: 3449988
[TBL] [Abstract][Full Text] [Related]
22. Allergic contact dermatitis caused by paromomycin.
Veraldi S; Benzecry V; Faraci AG; Nazzaro G
Contact Dermatitis; 2019 Nov; 81(5):393-394. PubMed ID: 31231805
[No Abstract] [Full Text] [Related]
23. Topical treatment of Old World cutaneous leishmaniasis caused by Leishmania major: a double-blind control study.
el-On J; Halevy S; Grunwald MH; Weinrauch L
J Am Acad Dermatol; 1992 Aug; 27(2 Pt 1):227-31. PubMed ID: 1430361
[TBL] [Abstract][Full Text] [Related]
24. Fluconazole for the treatment of cutaneous leishmaniasis.
Zvulunov A; Klaus S; Vardy D
N Engl J Med; 2002 Aug; 347(5):370-1; author reply 370-1. PubMed ID: 12151480
[No Abstract] [Full Text] [Related]
25. Non-ulcerative cutaneous leishmaniasis in Honduras fails to respond to topical paromomycin.
Neva FA; Ponce C; Ponce E; Kreutzer R; Modabber F; Olliaro P
Trans R Soc Trop Med Hyg; 1997; 91(4):473-5. PubMed ID: 9373659
[TBL] [Abstract][Full Text] [Related]
26. Comparison of topical paromomycin sulfate (twice/day) with intralesional meglumine antimoniate for the treatment of cutaneous leishmaniasis caused by L. major.
Shazad B; Abbaszadeh B; Khamesipour A
Eur J Dermatol; 2005; 15(2):85-7. PubMed ID: 15757817
[TBL] [Abstract][Full Text] [Related]
27. Protection of guinea pigs against cutaneous leishmaniasis by combined infection and chemotherapy.
El-On J; Witztum A; Schnur LF
Infect Immun; 1986 Feb; 51(2):704-6. PubMed ID: 3943909
[TBL] [Abstract][Full Text] [Related]
28. Leishmania major: bacterial contamination of cutaneous lesions in experimental animals.
el-On J; Sneier R; Elias E
Isr J Med Sci; 1992 Dec; 28(12):847-51. PubMed ID: 1286954
[TBL] [Abstract][Full Text] [Related]
29. Combined suboptimal schedules of topical paromomycin, meglumine antimoniate and miltefosine to treat experimental infection caused by Leishmania (Viannia) braziliensis.
de Morais-Teixeira E; Aguiar MG; Soares de Souza Lima B; Ferreira LA; Rabello A
J Antimicrob Chemother; 2015 Dec; 70(12):3283-90. PubMed ID: 26346991
[TBL] [Abstract][Full Text] [Related]
30. Treatment of cutaneous leishmaniasis with either topical paromomycin or intralesional meglumine antimoniate.
Faghihi G; Tavakoli-kia R
Clin Exp Dermatol; 2003 Jan; 28(1):13-6. PubMed ID: 12558620
[TBL] [Abstract][Full Text] [Related]
31. Comparative study of the efficacy of formulations containing fluconazole or paromomycin for topical treatment of infections by Leishmania (Leishmania) major and Leishmania (Leishmania) amazonensis.
Mussi SV; Fernandes AP; Ferreira LA
Parasitol Res; 2007 May; 100(6):1221-6. PubMed ID: 17206508
[TBL] [Abstract][Full Text] [Related]
32. Topical paromomycin with or without gentamicin for cutaneous leishmaniasis.
Ben Salah A; Ben Messaoud N; Guedri E; Zaatour A; Ben Alaya N; Bettaieb J; Gharbi A; Belhadj Hamida N; Boukthir A; Chlif S; Abdelhamid K; El Ahmadi Z; Louzir H; Mokni M; Morizot G; Buffet P; Smith PL; Kopydlowski KM; Kreishman-Deitrick M; Smith KS; Nielsen CJ; Ullman DR; Norwood JA; Thorne GD; McCarthy WF; Adams RC; Rice RM; Tang D; Berman J; Ransom J; Magill AJ; Grogl M
N Engl J Med; 2013 Feb; 368(6):524-32. PubMed ID: 23388004
[TBL] [Abstract][Full Text] [Related]
33. Topical Treatment of Cutaneous Leishmaniasis in Israel, Part 2.
Zur E
Int J Pharm Compd; 2019; 23(4):288-293. PubMed ID: 31315079
[TBL] [Abstract][Full Text] [Related]
34. Topical 15% Paromomycin-Aquaphilic for Bolivian Leishmania braziliensis Cutaneous Leishmaniasis: A Randomized, Placebo-controlled Trial.
Soto J; Soto P; Ajata A; Luque C; Tintaya C; Paz D; Rivero D; Berman J
Clin Infect Dis; 2019 Feb; 68(5):844-849. PubMed ID: 30260376
[TBL] [Abstract][Full Text] [Related]
35. Is paromomycin an effective and safe treatment against cutaneous leishmaniasis? A meta-analysis of 14 randomized controlled trials.
Kim DH; Chung HJ; Bleys J; Ghohestani RF
PLoS Negl Trop Dis; 2009; 3(2):e381. PubMed ID: 19221595
[TBL] [Abstract][Full Text] [Related]
36. Topical treatment of cutaneous leishmaniasis in Belize: in vitro and in vivo studies with Leishmania mexicana.
el-On J; Cawich F; Evans DA; Weinrauch L
Int J Parasitol; 1993 Feb; 23(1):121-7. PubMed ID: 8468127
[TBL] [Abstract][Full Text] [Related]
37. Combined topical paromomycin and oral miltefosine treatment of mice experimentally infected with Leishmania (Leishmania) major leads to reduction in both lesion size and systemic parasite burdens.
Aguiar MG; Silva DL; Nunan FA; Nunan EA; Fernandes AP; Ferreira LA
J Antimicrob Chemother; 2009 Dec; 64(6):1234-40. PubMed ID: 19825819
[TBL] [Abstract][Full Text] [Related]
38. Leishmania major: histopathological responses before and after topical treatment in experimental animals.
El-On J; Lang E; Kuperman O; Avinoach I
Exp Parasitol; 1989 Feb; 68(2):144-54. PubMed ID: 2924878
[TBL] [Abstract][Full Text] [Related]
39. Comparing the efficiency of topical paromomycin with intralesional meglumine antimoniate for cutaneous leishmaniasis.
Moosavi Z; Nakhli A; Rassaii S
Int J Dermatol; 2005 Dec; 44(12):1064-5. PubMed ID: 16409282
[No Abstract] [Full Text] [Related]
40. Cutaneous leishmaniasis on an unusual site--the glans penis.
Grunwald MH; Amichai B; Trau H
Br J Urol; 1998 Dec; 82(6):928. PubMed ID: 9883247
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
